Journal
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
Volume 70, Issue 12, Pages 3585-3595Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jafc.1c06289
Keywords
chronic diseases; bioactive peptides; protein hydrolysate; clinical trials; commercialization
Funding
- Natural Sciences and Engineering Research Council of Canada (NSERC)
Ask authors/readers for more resources
Food-derived bioactive peptides and protein hydrolysates have gained attention as diet-based strategies for preventing and mitigating chronic diseases, but their clinical translation is limited by a lack of understanding of their mechanisms of action and pharmacokinetics. Commercialization is also hindered by limited information on efficacy, safety, bitter taste, and cost-effective production methods.
Chronic diseases, including metabolic diseases, have become a worldwide public health issue. Research regarding the use of bioactive peptides or protein hydrolysates derived from food, as the diet-based strategies for the prevention and mitigation of chronic diseases, has increased exponentially in the past decades. Numerous in vitro and in vivo studies report the efficacy and safety of food-derived bioactive peptides and protein hydrolysates as antihypertensive, anti-inflammatory, antidiabetic, and antioxidant agents. However, despite promising preclinical results, an inadequate understanding of their mechanisms of action and pharmacokinetics restrict their clinical translation. Commercialization of bioactive peptides can be further hindered due to scarce information regarding their efficacy, safety, bitter taste, as well as the lack of a cost-effective method of production. This review provides an overview of the current clinical evidence and challenges to commercial applications of food-derived bioactive peptides and protein hydrolysates for the prevention and alleviation of chronic diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available